AcelRx Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    549300U8W781S4RBUE66
    ISIN
    US00444T2096 (ACRX)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    -€294.45K
    Gross margin
    -649.9%
    EBIT
    -€15.89M
    EBIT margin
    5,398.0%
    Net income
    -€18.93M
    Net margin
    6,428.0%

    Statement period: - (published )

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 14, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 12K $5.99K -7.5K Sell

    Add to watchlist

    Notifications